<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PPAR Res</journal-id><journal-id journal-id-type="publisher-id">PPAR</journal-id><journal-title>PPAR Research</journal-title><issn pub-type="ppub">1687-4757</issn><issn pub-type="epub">1687-4765</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19190780</article-id><article-id pub-id-type="pmc">2631651</article-id><article-id pub-id-type="doi">10.1155/2008/827096</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The Role of PPAR<italic>&#x003b3;</italic> Receptors and Leukotriene B<sub>4</sub> Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Adrian</surname><given-names>Thomas E.</given-names></name><xref ref-type="aff" rid="I1"><sup>1,2</sup></xref><xref ref-type="aff" rid="I2"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Hennig</surname><given-names>Rene</given-names></name><xref ref-type="aff" rid="I2"><sup>2,3</sup></xref><xref ref-type="aff" rid="I3"/></contrib><contrib contrib-type="author"><name><surname>Friess</surname><given-names>Helmut</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Xianzhong</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Physiology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates</aff><aff id="I2"><sup>2</sup>Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611-3008, USA</aff><aff id="I3"><sup>3</sup>Department of Surgery, Technische Universitaet Muenchen, 81675 Munich, Germany</aff><author-notes><corresp id="cor1">*Thomas E. Adrian: <email>tadrian@uaeu.ac.ae</email></corresp><fn fn-type="other"><p>Recommended by Dipak Panigrahy</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>27</day><month>1</month><year>2009</year></pub-date><volume>2008</volume><elocation-id>827096</elocation-id><history><date date-type="received"><day>12</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>22</day><month>10</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Thomas E. Adrian et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Pancreatic cancer is a devastating disease in which current therapies are inadequate. Separate lines of research have identified the 5-lipoxygenase/leukotriene B<sub>4</sub> receptor pathway and the PPAR<italic>&#x003b3;</italic> pathway as potential targets for prevention or treatment of this disease. LY293111 was originally designed as a potent leukotriene B<sub>4</sub> receptor antagonist for treatment of inflammatory conditions. LY293111 was also known to have inhibitory effects on 5-lipoxygenase, which is upstream of the production of leukotrienes. LY293111 was shown to have potent anticancer effects in pancreatic cancer and several other solid malignancies, where it caused cell cycle arrest and marked apoptosis. Subsequently, it came to light that LY293111 exhibited PPAR<italic>&#x003b3;</italic> agonist activity in addition to its effects on the 5-lipoxygenase pathway. This raises the question of which of the two targets is of greatest importance with regard to the anticancer effects of this agent. The evidence to date is not conclusive, but suggests that the effects of LY293111 may be mediated by both LTB<sub>4</sub> receptors and PPAR<italic>&#x003b3;</italic>.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>PancreaticCancer is a devastating disease withmore than 80% of all patients presenting with surgically inoperabletumors.  It remains the fourth leadingcause of cancer death in both men and women in the USA.  The median survival is usually less than sixmonths even with the addition of chemotherapy [<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B3">3</xref>].  Surgical resection is the only effectivetreatment option, but there are few long-term survivors even after apparentcurative resection [<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B3">3</xref>]. Alternativeeffective treatment strategies are desperately needed for this disease.</p><sec id="subsec1.1"><title>1.1. Fatty acids and human cancer</title><p>Epidemiological and animal studies show thata high fat consumption is associated with a higher incidence and growth oftumors at several specific organ sites including breast, pancreas, and prostate [<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B11">11</xref>]. Recentstudies indicate that diets containing a high proportion of polyunsaturatedomega-6 fatty acids (n&#x02212;6 FA), such as linoleic acid (the precursor ofarachidonic acid) are associated with a more advanced disease stage at the timeof diagnosis of several kinds of cancer [<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>]. In contrast,long-chain n&#x02212;3 fatty acids, such as docosahexaenoic acid and eicosapentaenoicacid (EPA) inhibit the growth and metastasis of several cancers includingpancreatic cancer [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B9">9</xref>]. Omega 3 fatty acids inhibit tumor growth by a numberof mechanisms including suppression of COX-2 expression and, for EPA at least,the alternative substrate produces different cyclooxygenase (PGE<sub>3</sub>)and lipoxygenase (LTB<sub>5</sub>) products that have anti-inflammatory and anticancereffects.</p></sec><sec id="subsec1.2"><title>1.2. Eicosanoid pathways</title><p>Arachidonic acid isa substrate for three distinctively different enzymatic pathways. Among them,prostaglandin endoperoxide synthases (cyclooxygenases) catalyze the committedstep that leads to prostaglandin biosynthesis [<xref ref-type="bibr" rid="B12">12</xref>&#x02013;<xref ref-type="bibr" rid="B14">14</xref>]. The secondpathway is the epoxygenase pathway that appears to have no role in cancer. Thethird pathway for metabolizing arachidonic acid, the lipoxygenase pathwaycatalyzes the incorporation of one oxygen molecule into polyunsaturated fattyacids to yield a 1-hydroperoxy-2, 4-trans, cis-pentadiene product [<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B16">16</xref>].  Mammalian lipoxygenases possessregiospecificity during interaction with substrate, and on this basis have beendesignated as arachidonate 5-, 12-, and 15-lipoxygenase (5-LOX, 12-LOX, and15-LOX) [<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B16">16</xref>].  The three distinct enzymes insert oxygen atcarbon 5, 12 or, 15 of arachidonic acid, and the primary product is 5S-, 12S-,or 15S-hydroperoxyeicosatetraenoic acid (5-, 12-, or 15-HPETE), which can befurther reduced by glutathione peroxidase to hydroxy forms (5-, 12-, 15-HETE),respectively [<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B16">16</xref>]. 5-LOX isnoteworthy because it is the only pathway that can turn arachidonic acid intoleukotrienes [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. The activity of 5-LOX is dependent upon a second factortermed 5-LOX-activating protein (FLAP) [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. Considerable effort has beenexpended by the pharmaceutical industry to produce inhibitors of FLAP, 5-LOX aswell as leukotriene antagonists, because the 5-LOX products, leukotrienes (LTB<sub>4</sub>,LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>) have been implicated asmediators of inflammation and immediate hypersensitivity reactions, inparticular, human bronchial asthma [<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>].</p></sec><sec id="subsec1.3"><title>1.3. Leukotriene receptor antagonists andthe development of LY293111</title><p>The pharmaceutical industry has focused on several targets to suppressleukotriene activity in inflammatory conditions such as bronchial asthma [<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. One approach is to directly inhibit 5-lipoxygenase activity, thereby blockingsecretion of all leukotrienes.  The mostwidely studied clinical inhibitor of 5-lipoxygenase is zileuton, which inhibitsthe active site of 5-lipoxygenase at concentrations that do notinhibit cyclooxygenase, 12-lipoxygenase, or 15-lipoxygenase [<xref ref-type="bibr" rid="B18">18</xref>&#x02013;<xref ref-type="bibr" rid="B22">22</xref>].  Another avenue to inhibit leukotrieneformation is via blocking FLAP activity, thus preventing cytoplasmic tomembrane translocation and activation of 5-lipoxygenase [<xref ref-type="bibr" rid="B16">16</xref>&#x02013;<xref ref-type="bibr" rid="B18">18</xref>]. MK-0591 is awidely used 5-lipoxygenase-activating protein inhibitor forbiomedical research [<xref ref-type="bibr" rid="B16">16</xref>&#x02013;<xref ref-type="bibr" rid="B18">18</xref>].  Even though it strongly inhibits 5-lipoxygenase activity and blocks leukotriene generation, its use in clinic islimited by marked side effects. The final pharmacological approach to blockleukotriene activity is to selectively block the actions of LTB<sub>4</sub> or the sulfidopeptide leukotrienes using specific receptor antagonists.</p><p>Several synthetic LTB<sub>4</sub> receptorantagonists have been developed. Early compounds included SC-41930;ONO-4057, which was orallyactive; LY223982, a benzophenone dicarboxylic acid; and LY255283 a hydroxyacetophenone [<xref ref-type="bibr" rid="B23">23</xref>&#x02013;<xref ref-type="bibr" rid="B27">27</xref>]. These lattertwo compounds from the Lilly Research Laboratories potently block LTB<sub>4</sub> binding to its receptors within the nM range and inhibit the biologicalfunctions of LTB<sub>4</sub> in vitro [<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>]. Unfortunately, theyshowed poor oral bioavailability [<xref ref-type="bibr" rid="B28">28</xref>]. In 1995, investigators at the LillyResearch Laboratories reported a new LTB<sub>4</sub> antagonist, LY293111. Thiscompound is a novel derivative of LY255283, but is orally stable and more potentas an LTB<sub>4</sub> receptor antagonist [<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>].  Compared with other LTB<sub>4</sub> receptorantagonists, LY293111 is superior at blocking the cellular functions induced byLTB<sub>4</sub> [<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B30">30</xref>].</p></sec><sec id="subsec1.4"><title>1.4. Inflammation, Cyclooxygenases,Lipoxygenases, and cancer</title><p>Theepidemiological data show a clear and strong association between chronicinflammatory conditions and cancer development, even though the conditionscausing inflammation may vary [<xref ref-type="bibr" rid="B31">31</xref>&#x02013;<xref ref-type="bibr" rid="B36">36</xref>].  It can be due to chronic infection caused bya virus, bacteria, or parasite or it may be due to noninfective, physical, orchemical irritant [<xref ref-type="bibr" rid="B31">31</xref>&#x02013;<xref ref-type="bibr" rid="B36">36</xref>].  For example, chronic infection with the bacterium <italic>Helicobacter pylori</italic> causes atrophic gastritis, which can lead todysplasia and adenocarcinoma [<xref ref-type="bibr" rid="B37">37</xref>]. Hepatitis B and C viruses account for more than 80% of cases ofhepatocellular carcinoma worldwide [<xref ref-type="bibr" rid="B34">34</xref>]. The inflammatory bowel diseases, ulcerative colitis and Crohn's disease,predispose to the development of cancers of the large bowel and/or terminalileum, although a causative infectious agent has never been conclusivelyidentified [<xref ref-type="bibr" rid="B38">38</xref>].  For noninfectiousinflammation, chronic reflux of gastric acid and bile into the distal esophaguscauses chemical injury and on the long-term can lead to Barrett's esophagus andeventually to esophageal adenocarcinoma [<xref ref-type="bibr" rid="B35">35</xref>]. Thus it is apparent that chronic inflammation is a common underlyingtheme in the development of many different malignancies.</p><p>Although the mechanisms for the association between inflammation andcancer are not fully understood, growth factors, cytokines, and chemokinesreleased into inflammatory environment are associated with tumor developmentand progression [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B36">36</xref>].  Highconcentrations of free radicals and nitric oxide can induce DNA damage andpromote cancer development [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B36">36</xref>]. Over the past decade, much attention has been paid on the role ofcyclooxygenases in cancer development, specifically its inducible isoform, thecyclooxygenase 2 (COX-2) [<xref ref-type="bibr" rid="B39">39</xref>&#x02013;<xref ref-type="bibr" rid="B41">41</xref>].  COX-2 is active within both inflamed andmalignant tissues [<xref ref-type="bibr" rid="B37">37</xref>&#x02013;<xref ref-type="bibr" rid="B39">39</xref>].  The expression of COX-2 and COX-2 metabolitesincreases during the multistage progression of tumors [<xref ref-type="bibr" rid="B39">39</xref>&#x02013;<xref ref-type="bibr" rid="B41">41</xref>]. By metabolizingarachidonic acid to prostaglandins, COX-2 induces cellular resistance toapoptosis, modulation of cellular adhesion and motility, promotion ofangiogenesis, and immunosuppression [<xref ref-type="bibr" rid="B42">42</xref>&#x02013;<xref ref-type="bibr" rid="B47">47</xref>].  Epidemiological data has implicated COX-2 inthe pathogenesis of a number of epithelial malignancies, especially colorectalcancer [<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>]. Inhibition of the enzyme with COX inhibitors is associatedwith a dramatic reduction in the incidence, morbidity and mortality ofcolorectal cancer [<xref ref-type="bibr" rid="B48">48</xref>&#x02013;<xref ref-type="bibr" rid="B51">51</xref>]. Recentattention has also been focused on the role of 5-LOX, 12-LOX, and 15-LOX incancer [<xref ref-type="bibr" rid="B52">52</xref>&#x02013;<xref ref-type="bibr" rid="B60">60</xref>]. Inpancreatic cancer, activation of the 5-LOX and 12-LOX pathways enhances cancercell proliferation, while the 15-LOX pathway is protective against cancerdevelopment [<xref ref-type="bibr" rid="B61">61</xref>&#x02013;<xref ref-type="bibr" rid="B64">64</xref>].</p></sec><sec id="subsec1.5"><title>1.5. The 5-lipoxygenase/leukotriene B<sub>4</sub> pathwayand cancer</title><p>Accumulatingevidence suggests that the 5-LOX pathway has profound influence on thedevelopment and progression of human cancers [<xref ref-type="bibr" rid="B61">61</xref>&#x02013;<xref ref-type="bibr" rid="B64">64</xref>].  5-LOX is overexpressed in pancreatic cancertissues but is not expressed in normal pancreatic ductal cells [<xref ref-type="bibr" rid="B65">65</xref>]. Furthermore,this pathway is already up-regulated in pancreatic intraepithelial neoplasias(PanINs), which are the precursor lesions of pancreatic adenocarcinoma [<xref ref-type="bibr" rid="B66">66</xref>].  Blockade of 5-LOX activity inhibitsproliferation and induces apoptosis in pancreatic cancer cells both in vitroand in vivo [<xref ref-type="bibr" rid="B67">67</xref>&#x02013;<xref ref-type="bibr" rid="B69">69</xref>].  Pancreatic cancer cells secrete LTB<sub>4</sub> and LTB<sub>4</sub> induces proliferation in these cells [<xref ref-type="bibr" rid="B62">62</xref>]. TwoG-protein-coupled LTB<sub>4</sub> receptors (BLT1 and BLT2) have been clonedand characterized. BLT1 and BLT2 are high- and low-affinity LTB<sub>4</sub> receptors, respectively, and form a gene cluster in humans. Both BLT1 and BLT2are up-regulated in pancreatic cancer tissues, and expression was seen in allof the tested pancreatic cancer cell lines [<xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B70">70</xref>]. As with other proteins inthe 5-LOX/LTB<sub>4</sub> pathway, BLT1 and BLT2 are already up-regulated inpancreatic intraepithelial neoplasias (PanIN lesions) which are the precursorsof pancreatic adenocarcinomas [<xref ref-type="bibr" rid="B70">70</xref>]. This suggests that they may be valuabletargets for chemoprevention.</p></sec><sec id="subsec1.6"><title>1.6. PPAR<italic>&#x003b3;</italic> and pancreatic cancer</title><p>Peroxisome proliferator activated receptor-<italic>&#x003b3;</italic>(PPAR<italic>&#x003b3;</italic>) is a member of the nuclear receptor superfamily of ligand-activatedtranscription factors. PPAR<italic>&#x003b3;</italic> is expressed at high levels in adipose tissue andplays a central role in adipocyte differentiation and energy homeostasis. Recent studies have implicated PPAR<italic>&#x003b3;</italic> in the pathogenesis of several humanmalignancies [<xref ref-type="bibr" rid="B71">71</xref>&#x02013;<xref ref-type="bibr" rid="B74">74</xref>]. Previousstudies have suggested that PPAR<italic>&#x003b3;</italic> is up-regulated in pancreatic cancer [<xref ref-type="bibr" rid="B75">75</xref>]. Ourown studies, employing two separate commercially available antibodies, showthat PPAR<italic>&#x003b3;</italic> is expressed in pancreatic cancer, but that expression in the cancercells does not appear to be different from that in normal pancreatic ductal cells (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In contrast, PPAR<italic>&#x003b3;</italic> staining was seen in the islets surrounding cancers, butnot in islet cells from normal pancreatic tissues obtained from multiorgandonors (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In animal models,PPAR<italic>&#x003b3;</italic>ligands have preventive effects against chemical carcinogenesis [<xref ref-type="bibr" rid="B76">76</xref>]. Several studieshave shown that PPAR<italic>&#x003b3;</italic> agonists, including the natural ligand 15-deoxy-&#x00394;12,14-prostaglandin J2, and thiazolidinedione antidiabetic agents, such as citiglitizoneand rosiglitizone, inhibit growth and induce apoptosis in pancreatic cancer [<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B77">77</xref>&#x02013;<xref ref-type="bibr" rid="B81">81</xref>]. In contrast,one paper suggests induction of differentiation without apoptosis [<xref ref-type="bibr" rid="B82">82</xref>]. Theapoptosis appears to be preceded by a morphological change to a more differentiatedcell type which perhaps undergoes apoptosis when DNA repair turns out to be notpossible [<xref ref-type="bibr" rid="B80">80</xref>]. In some studies, PPAR<italic>&#x003b3;</italic> agonists also block invasion andangiogenesis [<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>]. However, this is controversial since PPAR<italic>&#x003b3;</italic> agonistsinduce secretion of vascular endothelial growth factor, which would have apromoting effect on metastatic tumor growth [<xref ref-type="bibr" rid="B85">85</xref>].</p></sec><sec id="subsec1.7"><title>1.7. LY293111 and cancer</title><p>As might be expected from the growth-stimulatory effects of LTB<sub>4</sub> in pancreatic cancer, the LTB<sub>4</sub> receptor antagonist, LY293111inhibits cancer growth and induces apoptosis both in vitro and in vivo [<xref ref-type="bibr" rid="B86">86</xref>&#x02013;<xref ref-type="bibr" rid="B89">89</xref>]. LY293111inhibits proliferation and induces apoptosis in a wide range of pancreaticcancer cell lines as well as cells of other tumor types, such as breast,prostate, and colon cancer cells [<xref ref-type="bibr" rid="B86">86</xref>&#x02013;<xref ref-type="bibr" rid="B89">89</xref>]. These effects on growth and apoptosisare both time and concentration dependent, with effects seen at 100&#x02013;500 nM in vitro [<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B87">87</xref>]. To confirm the involvementof LTB<sub>4</sub> receptors in mediating the effect of LY293111 on human pancreatic cancer cell proliferation, another selective LTB<sub>4</sub> receptor antagonist, U75302 was used in comparison with a selective LTD<sub>4</sub> antagonist, LY171883 [<xref ref-type="bibr" rid="B86">86</xref>]. U75302 inhibits the proliferation of pancreaticcancer cells; but it is less potent than LY293111 as expected from the lower receptor affinity of this drug [<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B90">90</xref>]. In contrast, the selective LTD<sub>4</sub> antagonist, LY171883 had no significant effect on pancreatic cancercell growth.  LY293111 causes cellcycle arrest in the S phase of the cell cycle with suppression of expression ofcyclin A, cyclin E, and cdk2. Inparallel with growth inhibition, LY293111 induced apoptosis in all cancer celllines tested [<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B87">87</xref>].  LY293111 induceddramatic morphological changes inhuman pancreatic cancer cellsfollowing a short period of treatment [<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B87">87</xref>]. The treated cells becamerounded and exhibited membrane blebbing, chromatin condensation, andnuclear fragmentation,finally they were detached from the microplate.Induction of DNA fragmentation by LY293111 was confirmed by TUNEL assay(terminal deoxynucleotidyl transferase-mediated nick end labeling)and apoptosis was also established by annexin V binding [<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B87">87</xref>]. Apoptosisis triggered through the mitochondrial pathway, with a change in the ratio ofproapoptotic proteins, such as Bax to antiapoptotic proteins, such as Bcl-2 andMcl-1, release of cytochrome C, activation of caspase (but not caspase 8), and subsequentactivation of the downstream caspase cascade with activation of caspase 3 andcaspase 7 and cleavage of the caspase 3 substrate, poly ADP-ribose polymerase(PARP) [<xref ref-type="bibr" rid="B87">87</xref>].</p><p>LY293111 markedly slows down the growth ofsubcutaneous xenografts of human pancreatic cancer in athymic mice at a dose of250 mg/kg/day [<xref ref-type="bibr" rid="B86">86</xref>]. To confirm the antipancreatic cancer effect of LY293111,pancreatic cancer cells with stable expression of enhanced greenfluorescent protein (GFP) wereorthotopically implanted into the duodenal lobe of the pancreas ofathymic mice. Our data show that LY293111 significantly inhibits the growth ofthe orthotopically implanted pancreatic cancer cells in concert with blocking metastaticspread to the liver and other organs [<xref ref-type="bibr" rid="B91">91</xref>]. LY293111 also dramatically increased the number of TUNEL positive cellsin pancreatic tumors harvested from the subcutaneous transplant experiments inathymic mice [<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B91">91</xref>].</p></sec><sec id="subsec1.8"><title>1.8. LY293111 as a PPAR<italic>&#x003b3;</italic> agonist</title><p>Followingthe disclosure of anticancer effects of LY293111, researchers at the LillyResearch Laboratories found that LY293111 is also a PPAR<italic>&#x003b3;</italic> agonist [<xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B93">93</xref>]. This finding was initiallybased on structural analysis and was supported by functional studies. The PPAR<italic>&#x003b3;</italic>agonist activity of LY293111 is evidenced by its ability to induce adipogenicdifferentiation in vitro [<xref ref-type="bibr" rid="B92">92</xref>]. Normalization of circulating glucose levels by LY293111in the ZDF rat diabetes model further suggests that LY293111 is anantidiabetic, PPAR<italic>&#x003b3;</italic>agonist [<xref ref-type="bibr" rid="B92">92</xref>]. Further studies suggested that the anticancer effect ofLY293111 might be mediated, at least in part, by PPAR<italic>&#x003b3;</italic> [<xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B93">93</xref>]. More extensive studies havesubsequently shown that LY293111 is also an inhibitor of 5-lipoxygenase,although this effect is less potent than the LTB<sub>4</sub> and PPAR<italic>&#x003b3;</italic> targets.</p></sec><sec id="subsec1.9"><title>1.9. Mechanisms by which LY293111functions in cancer</title><p>Since our findings suggest that allpancreatic cancer cells express both PPAR<italic>&#x003b3;</italic>and BLT1, it is possible that the anticancer effects of LY293111 could bemediated by either receptor or both receptors. It has been reported that PPAR<italic>&#x003b3;</italic>negative-expressing cancer cells are less responsive to LY293111-induced growthinhibition [<xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B93">93</xref>]. However, there is also evidence in favor of BLT1 being themajor target. Firstly, the effects of LY293111 on proliferation and apoptosisare extremely potent. A comparison between the effects of LY293111 and the PPAR<italic>&#x003b3;</italic>agonist, ciglitazone is shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>. As this figure shows, LY293111 isapproximately 50 times more potent than ciglitazone in inhibiting theproliferation of Panc-1 and S2-013 human pancreatic cancer cells. LY293111 wasalso more potent than another PPAR<italic>&#x003b3;</italic>agonist, rosiglitazone and the PPAR<italic>&#x003b1;</italic> agonist, WY-14643. The antiproliferativeeffects and induction of apoptosis are seen at 250 nM LY293111, which is muchlower than the IC<sub>50</sub> of the drug for PPAR<italic>&#x003b3;</italic> receptors (~4 <italic>&#x003bc;</italic>M) [<xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B93">93</xref>]. Indeed, its effectson cancer cells are more potent than several PPAR<italic>&#x003b3;</italic> agonists, including ciglitazone androsiglitazone. Secondly, LY293111 is able to completely inhibit the effects ofLTB<sub>4</sub> on proliferation and MAP kinase activation in pancreatic cancercells [<xref ref-type="bibr" rid="B62">62</xref>]. However, preliminary studies have shown that the antiproliferativeeffects of LY293111 in pancreatic cancer are not inhibited by the PPAR<italic>&#x003b3;</italic>antagonist, GW9662 in vitro (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Finally, data from our ownstudies and those of others show that PPAR<italic>&#x003b3;</italic> agonists induce cell cycle arrest in theG0/G1 phase, whereas LY293111 induces S phase cell cycle arrest [<xref ref-type="bibr" rid="B82">82</xref>, <xref ref-type="bibr" rid="B87">87</xref>].  It is even possible that anticancer effects ofLY293111 might also be partially mediated by other unknown mechanisms.  However, based on the current data, both theleukotriene B<sub>4</sub> receptor and PPAR<italic>&#x003b3;</italic> are likely to be involved in the antitumor activityof LY293111.</p></sec></sec><sec sec-type="section" id="sec2"><title>2. EFFECT OF LY293111 IN COMBINATION WITHOTHER AGENTS IN CANCER</title><p>Several studies have demonstrated thatLY293111 enhances anticancer effects of gemcitabine, which is widelyused as the standard therapy in pancreatic cancer patients in adjuvant andpalliative treatment settings [<xref ref-type="bibr" rid="B89">89</xref>, <xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B94">94</xref>]. Gemcitabine only improves survival bya few weeks, but clinical data show improvement in the quality of life forpancreatic cancer patients. The effects of LY293111 in combination with gemcitabinewere investigated in an orthotopic model of pancreatic cancer in athymic mice [<xref ref-type="bibr" rid="B91">91</xref>].  This model is superior to subcutaneoustransplantation since it is less likely to modify the biological characteristicof pancreatic cancer cells, providing a favourable growth environment for them. It also allows easy monitoring of hepatic and lymph node metastasis with GFPstable expressing cells.  In this model,animals without any treatment following implantation of GFP-expressing, S2-O13pancreatic cancer cells developed end-stage disease with invasive cancerobstructing the duodenum and bile duct [<xref ref-type="bibr" rid="B91">91</xref>]. The animals develop liver, lung,and lymph node metastases and eventually peritoneal carcinomatosis withmalignant ascites and cachexia [<xref ref-type="bibr" rid="B91">91</xref>]. Either gemcitabine or LY293111 alonesignificantly inhibited tumor growth and reduced the incidence of livermetastasis. However the combination of LY293111 and gemcitabine wassignificantly more effective than either treatment alone in blocking tumorgrowth [<xref ref-type="bibr" rid="B91">91</xref>].  Combined treatment alsosignificantly relieved tumor-induced cachexia and maintained stable bodyweights compared with either drug alone, and also significantly decreased theincidence of biliary obstruction and metastasis [<xref ref-type="bibr" rid="B91">91</xref>]. These experimentalresults show that combined therapy of gemcitabine and LY293111 potentlyinhibits the growth and metastases of the very rapidly growing and aggressivepancreatic adenocarcinoma and suggest that it might be a valuable way fortreatment of pancreatic cancer patients. LY293111 has also been shown toincrease the effectiveness of gemcitabine in a colon cancer model [<xref ref-type="bibr" rid="B89">89</xref>]. The invitro effects of LY293111 have been tested with other classicalchemotherapeutic agents. The effects of the active metabolite of irinotecan,SN-38 or the active metabolite of capecitabine, 5&#x02032;-DFUR were enhanced byLY293111 in multiple cell lines, including breast, bladder, and sarcoma cells [<xref ref-type="bibr" rid="B94">94</xref>].</p></sec><sec sec-type="section" id="sec3"><title>3. CLINICAL TRIALS WITH LY293111</title><p>Three phase I clinical trials withLY293111 alone or in combination with gemcitabine or irinotecan have beenreported. LY293111 was generally well tolerated [<xref ref-type="bibr" rid="B95">95</xref>&#x02013;<xref ref-type="bibr" rid="B97">97</xref>]. The sideeffects were mild to moderate; the major ones gastrointestinal with diarrheaand pain. These initial phase I trials looked promising and LY293111 could besafely administered orally [<xref ref-type="bibr" rid="B95">95</xref>&#x02013;<xref ref-type="bibr" rid="B97">97</xref>]. For example,in combination with gemcitabine, three patients had partial responses [<xref ref-type="bibr" rid="B96">96</xref>]. Onehad pancreatic cancer previously treated with gemcitabine, one with pancreaticcancer previously treated with 5-flurouracil and radiation, and one with non-small-celllung cancer treated with one prior regimen. Two phase II trials have beencompleted and preliminary data reported in abstract form [<xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>]. One of thesecompared the combination of LY293111 with gemcitabine compared with gemcitabinewith placebo in pancreatic cancer [<xref ref-type="bibr" rid="B98">98</xref>]. The second compared LY293111 withcisplatin and gemcitabine versus the placebo combined with the latter two drugsin patients with non-small-cell lung cancer [<xref ref-type="bibr" rid="B99">99</xref>]. Unfortunately, LY293111 didnot improve progression-free survival in either of these two trials [<xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>].</p></sec><sec sec-type="section" id="sec4"><title>4. CONCLUSIONS</title><p>LY293111 is an interesting compound that has biological effects on several differenttargets. It acts as an antagonist on LTB<sub>4</sub> receptors, as a PPAR<italic>&#x003b3;</italic> agonistand as a 5-lipoxygenase inhibitor. Indeed, some investigators have referred toLY293111 as a multiple eicosanoid pathway inhibitor [<xref ref-type="bibr" rid="B94">94</xref>, <xref ref-type="bibr" rid="B99">99</xref>]. Since LY293111has anticancer effects on multiple tumor types, the target involved inmediating the effects of the drug is clearly of interest. The evidence to dateis not conclusive, but suggests that effects may be mediated by both LTB<sub>4</sub> receptors and PPAR<italic>&#x003b3;</italic>. Preliminary reports regarding the phase II clinical trials have unfortunatelybeen disappointing. It remains unknown whether this compound will eventuallyfind a use in the clinic for cancer therapy; however this recent clinicalexperience perhaps makes this unlikely now.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jafari</surname><given-names>M</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name></person-group><article-title>Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal intergroup pancreatic cancer task force</article-title><source><italic>Surgical Oncology Clinics of North America</italic></source><year>2004</year><volume>13</volume><issue>4</issue><fpage>751</fpage><lpage>760</lpage><pub-id pub-id-type="pmid">15350946</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alexakis</surname><given-names>N</given-names></name><name><surname>Halloran</surname><given-names>C</given-names></name><name><surname>Raraty</surname><given-names>M</given-names></name><name><surname>Ghaneh</surname><given-names>P</given-names></name><name><surname>Sutton</surname><given-names>R</given-names></name><name><surname>Neoptolemos</surname><given-names>JP</given-names></name></person-group><article-title>Current standards of surgery for pancreatic cancer</article-title><source><italic>British Journal of Surgery</italic></source><year>2004</year><volume>91</volume><issue>11</issue><fpage>1410</fpage><lpage>1427</lpage><pub-id pub-id-type="pmid">15499648</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Carroll</surname><given-names>S</given-names></name><name><surname>Apte</surname><given-names>M</given-names></name><name><surname>Keogh</surname><given-names>G</given-names></name></person-group><article-title>Modern management of pancreatic carcinoma</article-title><source><italic>Internal Medicine Journal</italic></source><year>2004</year><volume>34</volume><issue>8</issue><fpage>475</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">15317546</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fay</surname><given-names>MP</given-names></name><name><surname>Freedman</surname><given-names>LS</given-names></name><name><surname>Clifford</surname><given-names>CK</given-names></name><name><surname>Midthune</surname><given-names>DN</given-names></name></person-group><article-title>Effect of different types and amounts of fat on the development of mammary tumors in rodents: a review</article-title><source><italic>Cancer Research</italic></source><year>1997</year><volume>57</volume><issue>18</issue><fpage>3979</fpage><lpage>3988</lpage><pub-id pub-id-type="pmid">9307282</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clerc</surname><given-names>P</given-names></name><name><surname>Bensaadi</surname><given-names>N</given-names></name><name><surname>Pradel</surname><given-names>P</given-names></name><name><surname>Estival</surname><given-names>A</given-names></name><name><surname>Clemente</surname><given-names>F</given-names></name><name><surname>Vaysse</surname><given-names>N</given-names></name></person-group><article-title>Lipid-dependent proliferation of pancreatic cancer cell lines</article-title><source><italic>Cancer Research</italic></source><year>1991</year><volume>51</volume><issue>14</issue><fpage>3633</fpage><lpage>3638</lpage><pub-id pub-id-type="pmid">2065320</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dao</surname><given-names>TL</given-names></name><name><surname>Hilf</surname><given-names>R</given-names></name></person-group><article-title>Dietary fat and breast cancer: a search for mechanisms</article-title><source><italic>Advances in Experimental Medicine and Biology</italic></source><year>1992</year><volume>322</volume><fpage>223</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">1442297</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karmali</surname><given-names>R</given-names></name></person-group><article-title>n-3 fatty acids: biochemical actions in cancer</article-title><source><italic>Journal of Nutritional Science and Vitaminology</italic></source><year>1992</year><fpage>148</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">1297728</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>DP</given-names></name><name><surname>Connolly</surname><given-names>JM</given-names></name></person-group><article-title>Dietary fat and breast cancer metastasis by human tumor xenografts</article-title><source><italic>Breast Cancer Research and Treatment</italic></source><year>1997</year><volume>46</volume><issue>2-3</issue><fpage>225</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">9478277</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>DP</given-names></name></person-group><article-title>Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies</article-title><source><italic>American Journal of Clinical Nutrition</italic></source><year>1997</year><volume>66</volume><issue>supplement 6</issue><fpage>1513S</fpage><lpage>1522S</lpage><pub-id pub-id-type="pmid">9394709</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>SM</given-names></name><name><surname>Hagerman</surname><given-names>RA</given-names></name><name><surname>Li-Stiles</surname><given-names>E</given-names></name><etal/></person-group><article-title>Arachidonate has protumor-promoting action that is inhibited by linoleate in mouse skin carcinogenesis</article-title><source><italic>Journal of Nutrition</italic></source><year>1996</year><volume>126</volume><issue>supplement 4</issue><fpage>1099S</fpage><lpage>1104S</lpage><pub-id pub-id-type="pmid">8642440</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ziboh</surname><given-names>VA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Fischer</surname><given-names>SM</given-names></name><name><surname>Slaga</surname><given-names>TJ</given-names></name></person-group><article-title>Arachidonic acid metabolism in the skin</article-title><source><italic>Arachidonic Acid Metabolism and Tumor Promotion</italic></source><year>1985</year><publisher-loc>Boston, Mass, USA</publisher-loc><publisher-name>Martinus Nijhoff</publisher-name><fpage>5</fpage><lpage>20</lpage></citation></ref><ref id="B12"><label>12</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Simonson</surname><given-names>MS</given-names></name><name><surname>Wolfe</surname><given-names>JA</given-names></name><name><surname>Dunn</surname><given-names>MJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Sammuelsson</surname><given-names>B</given-names></name><name><surname>Ramwell</surname><given-names>P</given-names></name><name><surname>Paoletti</surname><given-names>R</given-names></name></person-group><article-title>Regulation of prostaglandin synthesis by differential expression of the gene encoding prostaglandin endoperoxide synthase</article-title><source><italic>Advances in Prostaglandin, Thromboxane and Leukotriene Research</italic></source><year>1990</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Raven Press</publisher-name><fpage>21</fpage><lpage>69</lpage></citation></ref><ref id="B13"><label>13</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>WL</given-names></name><name><surname>DeWitt</surname><given-names>DL</given-names></name><name><surname>Kraemer</surname><given-names>SA</given-names></name><etal/></person-group><person-group person-group-type="editor"><name><surname>Samuelsson</surname><given-names>B</given-names></name></person-group><article-title>Structure function relationships in sheep, mouse, and human prostaglandin endoperoxide G/H synthases</article-title><source><italic>Advances in Prostaglandin, Thromboxane and Leukotriene Research</italic></source><year>1990</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Raven Press</publisher-name></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holtzman</surname><given-names>MJ</given-names></name><name><surname>Zhang</surname><given-names>V</given-names></name><name><surname>Hussain</surname><given-names>H</given-names></name><name><surname>Roswit</surname><given-names>WT</given-names></name><name><surname>Wilson</surname><given-names>JD</given-names></name></person-group><article-title>Prostaglandin H synthase and lipoxygenase gene families in the epithelial cell barrier</article-title><source><italic>Annals of the New York Academy of Sciences</italic></source><year>1994</year><volume>744</volume><fpage>58</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">7825863</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Funk</surname><given-names>CD</given-names></name></person-group><article-title>The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice</article-title><source><italic>Biochimica et Biophysica Acta</italic></source><year>1996</year><volume>1304</volume><issue>1</issue><fpage>65</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">8944751</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Funk</surname><given-names>CD</given-names></name></person-group><article-title>Prostaglandins and leukotrienes: advances in eicosanoid biology</article-title><source><italic>Science</italic></source><year>2001</year><volume>294</volume><issue>5548</issue><fpage>1871</fpage><lpage>1875</lpage><pub-id pub-id-type="pmid">11729303</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peters-Golden</surname><given-names>M</given-names></name><name><surname>Brock</surname><given-names>TG</given-names></name></person-group><article-title>5-lipoxygenase and FLAP</article-title><source><italic>Prostaglandins Leukotrienes and Essential Fatty Acids</italic></source><year>2003</year><volume>69</volume><issue>2-3</issue><fpage>99</fpage><lpage>109</lpage></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sorkness</surname><given-names>CA</given-names></name></person-group><article-title>The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma</article-title><source><italic>Pharmacotherapy</italic></source><year>1997</year><volume>17</volume><issue>1, part 2</issue><fpage>50S</fpage><lpage>54S</lpage><pub-id pub-id-type="pmid">9017788</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Negro</surname><given-names>JM</given-names></name><name><surname>Miralles</surname><given-names>JC</given-names></name><name><surname>Ortiz</surname><given-names>JL</given-names></name><name><surname>Funes</surname><given-names>E</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>A</given-names></name></person-group><article-title>Biosynthesis inhibitors for leukotrienes in bronchial asthma</article-title><source><italic>Allergologia et Immunopathologia</italic></source><year>1997</year><volume>25</volume><issue>4</issue><fpage>209</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">9269512</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leff</surname><given-names>AR</given-names></name></person-group><article-title>Discovery of leukotrienes and development of antileukotriene agents</article-title><source><italic>Annals of Allergy, Asthma and Immunology</italic></source><year>2001</year><volume>86</volume><issue>6</issue><supplement>supplement 1</supplement><fpage>4</fpage><lpage>8</lpage></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Djuric</surname><given-names>SW</given-names></name><name><surname>Collins</surname><given-names>PW</given-names></name><name><surname>Jones</surname><given-names>PH</given-names></name><etal/></person-group><article-title>7-[3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2<italic>H</italic>- 1-benzopyran-2-carboxylic acid: an orally active selective leukotriene B<sub>4</sub> receptor antagonist</article-title><source><italic>Journal of Medicinal Chemistry</italic></source><year>1989</year><volume>32</volume><issue>6</issue><fpage>1145</fpage><lpage>1147</lpage><pub-id pub-id-type="pmid">2542550</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fretland</surname><given-names>DJ</given-names></name><name><surname>Widomski</surname><given-names>DL</given-names></name><name><surname>Zemaitis</surname><given-names>JM</given-names></name><name><surname>Djuri&#x00107;</surname><given-names>SW</given-names></name><name><surname>Shone</surname><given-names>RL</given-names></name></person-group><article-title>Effect of a leukotriene B<sub>4</sub> receptor antagonist on leukotriene B<sub>4</sub>-induced neutrophil chemotaxis in cavine dermis</article-title><source><italic>Inflammation</italic></source><year>1989</year><volume>13</volume><issue>5</issue><fpage>601</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">2553605</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>BS</given-names></name><name><surname>Villani-Price</surname><given-names>D</given-names></name><name><surname>Keith</surname><given-names>RH</given-names></name><etal/></person-group><article-title>SC-41930: an inhibitor of leukotriene B<sub>4</sub>-stimulated human neutrophil functions</article-title><source><italic>Prostaglandins</italic></source><year>1989</year><volume>38</volume><issue>6</issue><fpage>655</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">2561214</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kishikawa</surname><given-names>K</given-names></name><name><surname>Tateishi</surname><given-names>N</given-names></name><name><surname>Maruyama</surname><given-names>T</given-names></name><name><surname>Seo</surname><given-names>R</given-names></name><name><surname>Toda</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>T</given-names></name></person-group><article-title>ONO-4057, a novel orally active leukotriene B4 antagonist: effects on LTB<sub>4</sub>-induced neutrophil functions</article-title><source><italic>Prostaglandins</italic></source><year>1992</year><volume>44</volume><issue>4</issue><fpage>261</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">1332129</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kishikawa</surname><given-names>K</given-names></name><name><surname>Nakao</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Hamanaka</surname><given-names>N</given-names></name></person-group><article-title>Estimation of antagonistic activity of ONO-4057 against leukotriene B4 in humans</article-title><source><italic>Advances in Prostaglandin, Thromboxane, and Leukotriene Research</italic></source><year>1995</year><volume>23</volume><fpage>279</fpage><lpage>281</lpage></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gapinski</surname><given-names>DM</given-names></name><name><surname>Mallett</surname><given-names>BE</given-names></name><name><surname>Froelich</surname><given-names>LL</given-names></name><name><surname>Jackson</surname><given-names>WT</given-names></name></person-group><article-title>Benzophenone dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain</article-title><source><italic>Journal of Medicinal Chemistry</italic></source><year>1990</year><volume>33</volume><issue>10</issue><fpage>2807</fpage><lpage>2813</lpage><pub-id pub-id-type="pmid">2170648</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>WT</given-names></name><name><surname>Boyd</surname><given-names>RJ</given-names></name><name><surname>Froelich</surname><given-names>LL</given-names></name><name><surname>Mallett</surname><given-names>BE</given-names></name><name><surname>Gapinski</surname><given-names>DM</given-names></name></person-group><article-title>Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982</article-title><source><italic>Journal of Pharmacology and Experimental Therapeutics</italic></source><year>1992</year><volume>263</volume><issue>3</issue><fpage>1009</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">1335049</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marder</surname><given-names>P</given-names></name><name><surname>Sawyer</surname><given-names>JS</given-names></name><name><surname>Froelich</surname><given-names>LL</given-names></name><name><surname>Mann</surname><given-names>LL</given-names></name><name><surname>Spaethe</surname><given-names>SM</given-names></name></person-group><article-title>Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy] phenoxy]benzoic acid (LY293111), a novel leukotriene B<sub>4</sub> receptor antagonist</article-title><source><italic>Biochemical Pharmacology</italic></source><year>1995</year><volume>49</volume><issue>11</issue><fpage>1683</fpage><lpage>1690</lpage><pub-id pub-id-type="pmid">7786309</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawyer</surname><given-names>JS</given-names></name><name><surname>Bach</surname><given-names>NJ</given-names></name><name><surname>Baker</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B<sub>4</sub> receptor antagonist</article-title><source><italic>Journal of Medicinal Chemistry</italic></source><year>1995</year><volume>38</volume><issue>22</issue><fpage>4411</fpage><lpage>4432</lpage><pub-id pub-id-type="pmid">7473568</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawyer</surname><given-names>JS</given-names></name></person-group><article-title>LY293111Na</article-title><source><italic>Drugs of the Future</italic></source><year>1996</year><volume>21</volume><fpage>610</fpage><lpage>614</lpage></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Inflammation and cancer</article-title><source><italic>Nature</italic></source><year>2002</year><volume>420</volume><issue>6917</issue><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">12490959</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macarthur</surname><given-names>M</given-names></name><name><surname>Hold</surname><given-names>GL</given-names></name><name><surname>El-Omar</surname><given-names>EM</given-names></name></person-group><article-title>Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy</article-title><source><italic>American Journal of Physiology</italic></source><year>2004</year><volume>286</volume><issue>4</issue><fpage>G515</fpage><lpage>G520</lpage><pub-id pub-id-type="pmid">15010360</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>WG</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name><name><surname>DeWeese</surname><given-names>TL</given-names></name><etal/></person-group><article-title>The role of inflammation in the pathogenesis of prostate cancer</article-title><source><italic>The Journal of Urology</italic></source><year>2004</year><volume>172</volume><issue>5</issue><supplement>supplement 1</supplement><fpage>S6</fpage><lpage>S12</lpage><pub-id pub-id-type="pmid">15535435</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Br&#x000e9;chot</surname><given-names>C</given-names></name></person-group><article-title>Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms</article-title><source><italic>Gastroenterology</italic></source><year>2004</year><volume>127</volume><issue>5</issue><supplement>supplement 1</supplement><fpage>S56</fpage><lpage>S61</lpage><pub-id pub-id-type="pmid">15508104</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tannapfel</surname><given-names>A</given-names></name></person-group><article-title>Molecular findings in Barrett's epithelium</article-title><source><italic>Digestive Diseases</italic></source><year>2004</year><volume>22</volume><issue>2</issue><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">15383753</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>At the crossroads of inflammation and cancer</article-title><source><italic>Cell</italic></source><year>2004</year><volume>118</volume><issue>6</issue><fpage>671</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">15369667</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoicov</surname><given-names>C</given-names></name><name><surname>Saffari</surname><given-names>R</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Hasyagar</surname><given-names>C</given-names></name><name><surname>Houghton</surname><given-names>J</given-names></name></person-group><article-title>Molecular biology of gastric cancer: helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling</article-title><source><italic>Gene</italic></source><year>2004</year><volume>341</volume><issue>1-2</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">15474284</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feld</surname><given-names>AD</given-names></name></person-group><article-title>Malpractice risks associated with colon cancer and inflammatory bowel disease</article-title><source><italic>American Journal of Gastroenterology</italic></source><year>2004</year><volume>99</volume><issue>9</issue><fpage>1641</fpage><lpage>1644</lpage><pub-id pub-id-type="pmid">15330895</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zha</surname><given-names>S</given-names></name><name><surname>Yegnasubramanian</surname><given-names>V</given-names></name><name><surname>Nelson</surname><given-names>WG</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name></person-group><article-title>Cyclooxygenases in cancer: progress and perspective</article-title><source><italic>Cancer Letters</italic></source><year>2004</year><volume>215</volume><issue>1</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15374627</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Woude</surname><given-names>CJ</given-names></name><name><surname>Kleibeuker</surname><given-names>JH</given-names></name><name><surname>Jansen</surname><given-names>PLM</given-names></name><name><surname>Moshage</surname><given-names>H</given-names></name></person-group><article-title>Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract</article-title><source><italic>Apoptosis</italic></source><year>2004</year><volume>9</volume><issue>2</issue><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">15004509</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farrow</surname><given-names>B</given-names></name><name><surname>Evers</surname><given-names>BM</given-names></name></person-group><article-title>Inflammation and the development of pancreatic cancer</article-title><source><italic>Surgical Oncology</italic></source><year>2002</year><volume>10</volume><issue>4</issue><fpage>153</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">12020670</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trifan</surname><given-names>OC</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name></person-group><article-title>Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis</article-title><source><italic>Journal of Cellular and Molecular Medicine</italic></source><year>2003</year><volume>7</volume><issue>3</issue><fpage>207</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">14594546</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Tong</surname><given-names>W-G</given-names></name><name><surname>Adrian</surname><given-names>TE</given-names></name></person-group><article-title>Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer</article-title><source><italic>Pancreatology</italic></source><year>2001</year><volume>1</volume><issue>4</issue><fpage>291</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">12120207</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Prescott</surname><given-names>SM</given-names></name></person-group><article-title>Many actions of cyclooxygenase-2 in cellular dynamics and in cancer</article-title><source><italic>Journal of Cellular Physiology</italic></source><year>2002</year><volume>190</volume><issue>3</issue><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">11857443</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fosslien</surname><given-names>E</given-names></name></person-group><article-title>Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis</article-title><source><italic>Annals of Clinical and Laboratory Science</italic></source><year>2001</year><volume>31</volume><issue>4</issue><fpage>325</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">11688844</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gately</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>WW</given-names></name></person-group><article-title>Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy</article-title><source><italic>Seminars in Oncology</italic></source><year>2004</year><volume>31</volume><issue>supplement 7</issue><fpage>2</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">15179620</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>R&#x000fc;egg</surname><given-names>C</given-names></name><name><surname>Dormond</surname><given-names>O</given-names></name><name><surname>Mariotti</surname><given-names>A</given-names></name></person-group><article-title>Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis</article-title><source><italic>Biochimica et Biophysica Acta</italic></source><year>2004</year><volume>1654</volume><issue>1</issue><fpage>51</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">14984767</pub-id></citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thun</surname><given-names>MJ</given-names></name></person-group><article-title>Aspirin, NSAIDs, and digestive tract cancers</article-title><source><italic>Cancer and Metastasis Reviews</italic></source><year>1994</year><volume>13</volume><issue>3-4</issue><fpage>269</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">7712589</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thun</surname><given-names>MJ</given-names></name></person-group><article-title>NSAID use and decreased risk of gastrointestinal cancers</article-title><source><italic>Gastroenterology Clinics of North America</italic></source><year>1996</year><volume>25</volume><issue>2</issue><fpage>333</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">9229576</pub-id></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>GN</given-names></name></person-group><article-title>Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer</article-title><source><italic>The FASEB Journal</italic></source><year>1997</year><volume>11</volume><issue>4</issue><fpage>234</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">9068612</pub-id></citation></ref><ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>JA</given-names></name><name><surname>Sandler</surname><given-names>RS</given-names></name></person-group><article-title>Nonsteroidal anti-inflammatory drugs and cancer prevention</article-title><source><italic>Annual Review of Medicine</italic></source><year>2000</year><volume>51</volume><fpage>511</fpage><lpage>523</lpage></citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>TJ</given-names></name><name><surname>Chan</surname><given-names>C-Y</given-names></name><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Adrian</surname><given-names>TE</given-names></name></person-group><article-title>Lipoxygenase inhibitors for the treatment of pancreatic cancer</article-title><source><italic>Expert Review of Anticancer Therapy</italic></source><year>2003</year><volume>3</volume><issue>4</issue><fpage>525</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">12934664</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>CE</given-names></name><name><surname>Ghosh</surname><given-names>J</given-names></name></person-group><article-title>Lipoxygenase inhibition in prostate cancer</article-title><source><italic>European Urology</italic></source><year>1999</year><volume>35</volume><issue>5-6</issue><fpage>395</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">10325495</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>WG</given-names></name><name><surname>Douglas-Jones</surname><given-names>A</given-names></name><name><surname>Mansel</surname><given-names>RE</given-names></name></person-group><article-title>Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer</article-title><source><italic>Prostaglandins Leukotrienes and Essential Fatty Acids</italic></source><year>2003</year><volume>69</volume><issue>4</issue><fpage>275</fpage><lpage>281</lpage></citation></ref><ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>M</given-names></name><name><surname>Yoshimura</surname><given-names>R</given-names></name><name><surname>Mitsuhashi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors</article-title><source><italic>International Journal of Oncology</italic></source><year>2004</year><volume>24</volume><issue>4</issue><fpage>821</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">15010818</pub-id></citation></ref><ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Ahmad</surname><given-names>N</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Bostwick</surname><given-names>DG</given-names></name><name><surname>Mukhtar</surname><given-names>H</given-names></name></person-group><article-title>Lipoxygenase-5 is overexpressed in prostate adenocarcinoma</article-title><source><italic>Cancer</italic></source><year>2001</year><volume>91</volume><issue>4</issue><fpage>737</fpage><lpage>743</lpage><pub-id pub-id-type="pmid">11241241</pub-id></citation></ref><ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>J</given-names></name><name><surname>Myers</surname><given-names>CE</given-names></name></person-group><article-title>Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1998</year><volume>95</volume><issue>22</issue><fpage>13182</fpage><lpage>13187</lpage><pub-id pub-id-type="pmid">9789062</pub-id></citation></ref><ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>J</given-names></name><name><surname>Myers</surname><given-names>CE</given-names></name></person-group><article-title>Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells</article-title><source><italic>Advances in Experimental Medicine and Biology</italic></source><year>1999</year><volume>469</volume><fpage>577</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">10667385</pub-id></citation></ref><ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KM</given-names></name><name><surname>Seed</surname><given-names>T</given-names></name><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Ou</surname><given-names>D</given-names></name><name><surname>Alrefai</surname><given-names>WA</given-names></name><name><surname>Harris</surname><given-names>JE</given-names></name></person-group><article-title>Five-lipoxygenase inhibitors reduce PANC-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid</article-title><source><italic>Anticancer Research</italic></source><year>1998</year><volume>18</volume><issue>2</issue><fpage>791</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">9615721</pub-id></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>M</given-names></name><name><surname>Catalano</surname><given-names>A</given-names></name><name><surname>Nutini</surname><given-names>M</given-names></name><etal/></person-group><article-title>5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor</article-title><source><italic>The FASEB Journal</italic></source><year>2001</year><volume>15</volume><issue>13</issue><fpage>2326</fpage><lpage>2336</lpage><pub-id pub-id-type="pmid">11689458</pub-id></citation></ref><ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Tong</surname><given-names>W-G</given-names></name><name><surname>Adrian</surname><given-names>TE</given-names></name></person-group><article-title>Multiple signal pathways are involved in the mitogenic effect of 5(<italic>S</italic>)-HETE in human pancreatic cancer</article-title><source><italic>Oncology</italic></source><year>2003</year><volume>65</volume><issue>4</issue><fpage>285</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">14707447</pub-id></citation></ref><ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>W-G</given-names></name><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Talamonti</surname><given-names>MS</given-names></name><name><surname>Bell</surname><given-names>RH</given-names></name><name><surname>Adrian</surname><given-names>TE</given-names></name></person-group><article-title>LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2005</year><volume>335</volume><issue>3</issue><fpage>949</fpage><lpage>956</lpage><pub-id pub-id-type="pmid">16105664</pub-id></citation></ref><ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Tong</surname><given-names>W-G</given-names></name><name><surname>Adrian</surname><given-names>TE</given-names></name></person-group><article-title>12-lipoxygenase metabolite 12(<italic>S</italic>)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation</article-title><source><italic>International Journal of Cancer</italic></source><year>2001</year><volume>94</volume><issue>5</issue><fpage>630</fpage><lpage>636</lpage></citation></ref><ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hennig</surname><given-names>R</given-names></name><name><surname>Kehl</surname><given-names>T</given-names></name><name><surname>Noor</surname><given-names>S</given-names></name><etal/></person-group><article-title>15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth</article-title><source><italic>Neoplasia</italic></source><year>2007</year><volume>9</volume><issue>11</issue><fpage>917</fpage><lpage>926</lpage><pub-id pub-id-type="pmid">18030360</pub-id></citation></ref><ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hennig</surname><given-names>R</given-names></name><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Tong</surname><given-names>W-G</given-names></name><etal/></person-group><article-title>5-lipoxygenase and leukotriene B<sub>4</sub> receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue</article-title><source><italic>American Journal of Pathology</italic></source><year>2002</year><volume>161</volume><issue>2</issue><fpage>421</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">12163367</pub-id></citation></ref><ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hennig</surname><given-names>R</given-names></name><name><surname>Grippo</surname><given-names>P</given-names></name><name><surname>Ding</surname><given-names>X-Z</given-names></name><etal/></person-group><article-title>5-lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions</article-title><source><italic>Cancer Research</italic></source><year>2005</year><volume>65</volume><issue>14</issue><fpage>6011</fpage><lpage>6016</lpage><pub-id pub-id-type="pmid">16024599</pub-id></citation></ref><ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Kuszynski</surname><given-names>CA</given-names></name><name><surname>El-Metwally</surname><given-names>TH</given-names></name><name><surname>Adrian</surname><given-names>TE</given-names></name></person-group><article-title>Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>1999</year><volume>266</volume><issue>2</issue><fpage>392</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">10600514</pub-id></citation></ref><ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Iversen</surname><given-names>P</given-names></name><name><surname>Cluck</surname><given-names>MW</given-names></name><name><surname>Knezetic</surname><given-names>JA</given-names></name><name><surname>Adrian</surname><given-names>TE</given-names></name></person-group><article-title>Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>1999</year><volume>261</volume><issue>1</issue><fpage>218</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">10405349</pub-id></citation></ref><ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>WG</given-names></name><name><surname>Ding</surname><given-names>XZ</given-names></name><name><surname>Witt</surname><given-names>RC</given-names></name><name><surname>Adrian</surname><given-names>TE</given-names></name></person-group><article-title>Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway</article-title><source><italic>Molecular Cancer Therapeutics</italic></source><year>2002</year><volume>1</volume><issue>11</issue><fpage>929</fpage><lpage>935</lpage><pub-id pub-id-type="pmid">12481414</pub-id></citation></ref><ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hennig</surname><given-names>R</given-names></name><name><surname>Osman</surname><given-names>T</given-names></name><name><surname>Esposito</surname><given-names>I</given-names></name><etal/></person-group><article-title>BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation</article-title><source><italic>British Journal of Cancer</italic></source><year>2008</year><volume>99</volume><issue>7</issue><fpage>1064</fpage><lpage>1073</lpage><pub-id pub-id-type="pmid">18781173</pub-id></citation></ref><ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roberts-Thomson</surname><given-names>SJ</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment</article-title><source><italic>Immunology and Cell Biology</italic></source><year>2000</year><volume>78</volume><issue>4</issue><fpage>436</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">10947870</pub-id></citation></ref><ref id="B72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kopelovich</surname><given-names>L</given-names></name><name><surname>Fay</surname><given-names>JR</given-names></name><name><surname>Glazer</surname><given-names>RI</given-names></name><name><surname>Crowell</surname><given-names>JA</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents</article-title><source><italic>Molecular Cancer Therapeutics</italic></source><year>2002</year><volume>1</volume><issue>5</issue><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">12489852</pub-id></citation></ref><ref id="B73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> and cancers</article-title><source><italic>Clinical Cancer Research</italic></source><year>2003</year><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12538445</pub-id></citation></ref><ref id="B74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grommes</surname><given-names>C</given-names></name><name><surname>Landreth</surname><given-names>GE</given-names></name><name><surname>Heneka</surname><given-names>MT</given-names></name></person-group><article-title>Antineoplastic effects of peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> agonists</article-title><source><italic>Lancet Oncology</italic></source><year>2004</year><volume>5</volume><issue>7</issue><fpage>419</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">15231248</pub-id></citation></ref><ref id="B75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motomura</surname><given-names>W</given-names></name><name><surname>Okumura</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Obara</surname><given-names>T</given-names></name><name><surname>Kohgo</surname><given-names>Y</given-names></name></person-group><article-title>Activation of peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> by troglitazone inhibits cell growth through the increase of p27(Kip1) in human pancreatic carcinoma cells</article-title><source><italic>Cancer Research</italic></source><year>2000</year><volume>60</volume><issue>19</issue><fpage>5558</fpage><lpage>5564</lpage><pub-id pub-id-type="pmid">11034103</pub-id></citation></ref><ref id="B76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RG</given-names></name><name><surname>Williamson</surname><given-names>E</given-names></name><name><surname>Patel</surname><given-names>MK</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group><article-title>A ligand of peroxisome proliferator-activated receptor <italic>&#x003b3;</italic>, retinoids, and prevention of preneoplastic mammary lesions</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>2000</year><volume>92</volume><issue>5</issue><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">10699072</pub-id></citation></ref><ref id="B77"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Fujimoto</surname><given-names>Y</given-names></name><name><surname>Tsuchida</surname><given-names>A</given-names></name><name><surname>Kawasaki</surname><given-names>Y</given-names></name><name><surname>Kuwada</surname><given-names>Y</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name></person-group><article-title>Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer</article-title><source><italic>Pathobiology</italic></source><year>2001</year><volume>69</volume><issue>5</issue><fpage>258</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">12107343</pub-id></citation></ref><ref id="B78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Itami</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>G</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Ligands for peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> inhibit growth of pancreatic cancers both in vitro and in vivo</article-title><source><italic>International Journal of Cancer</italic></source><year>2001</year><volume>94</volume><issue>3</issue><fpage>370</fpage><lpage>376</lpage></citation></ref><ref id="B79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eibl</surname><given-names>G</given-names></name><name><surname>Wente</surname><given-names>MN</given-names></name><name><surname>Reber</surname><given-names>HA</given-names></name><name><surname>Hines</surname><given-names>OJ</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> induces pancreatic cancer cell apoptosis</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2001</year><volume>287</volume><issue>2</issue><fpage>522</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">11554760</pub-id></citation></ref><ref id="B80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawa</surname><given-names>S</given-names></name><name><surname>Nikaido</surname><given-names>T</given-names></name><name><surname>Unno</surname><given-names>H</given-names></name><name><surname>Usuda</surname><given-names>N</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Kiyosawa</surname><given-names>K</given-names></name></person-group><article-title>Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR<italic>&#x003b3;</italic> ligand troglitazone</article-title><source><italic>Pancreas</italic></source><year>2002</year><volume>24</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11741176</pub-id></citation></ref><ref id="B81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Farrow</surname><given-names>BJ</given-names></name><name><surname>Evers</surname><given-names>BM</given-names></name></person-group><article-title>Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2</article-title><source><italic>Pancreas</italic></source><year>2004</year><volume>28</volume><issue>2</issue><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">15028947</pub-id></citation></ref><ref id="B82"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ceni</surname><given-names>E</given-names></name><name><surname>Mello</surname><given-names>T</given-names></name><name><surname>Tarocchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells</article-title><source><italic>World Journal of Gastroenterology</italic></source><year>2005</year><volume>11</volume><issue>8</issue><fpage>1122</fpage><lpage>1130</lpage><pub-id pub-id-type="pmid">15754392</pub-id></citation></ref><ref id="B83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motomura</surname><given-names>W</given-names></name><name><surname>Nagamine</surname><given-names>M</given-names></name><name><surname>Tanno</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells</article-title><source><italic>Journal of Gastroenterology</italic></source><year>2004</year><volume>39</volume><issue>5</issue><fpage>461</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">15175945</pub-id></citation></ref><ref id="B84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname><given-names>A</given-names></name><name><surname>Ceni</surname><given-names>E</given-names></name><name><surname>Crabb</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR<italic>&#x003b3;</italic> independent mechanisms</article-title><source><italic>Gut</italic></source><year>2004</year><volume>53</volume><issue>11</issue><fpage>1688</fpage><lpage>1697</lpage><pub-id pub-id-type="pmid">15479693</pub-id></citation></ref><ref id="B85"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eibl</surname><given-names>G</given-names></name><name><surname>Takata</surname><given-names>Y</given-names></name><name><surname>Boros</surname><given-names>LG</given-names></name><etal/></person-group><article-title>Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor</article-title><source><italic>Cancer Research</italic></source><year>2005</year><volume>65</volume><issue>3</issue><fpage>982</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">15705899</pub-id></citation></ref><ref id="B86"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>W-G</given-names></name><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Hennig</surname><given-names>R</given-names></name><etal/></person-group><article-title>Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells</article-title><source><italic>Clinical Cancer Research</italic></source><year>2002</year><volume>8</volume><issue>10</issue><fpage>3232</fpage><lpage>3242</lpage><pub-id pub-id-type="pmid">12374694</pub-id></citation></ref><ref id="B87"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>W-G</given-names></name><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Talamonti</surname><given-names>MS</given-names></name><name><surname>Bell</surname><given-names>RH</given-names></name><name><surname>Adrian</surname><given-names>TE</given-names></name></person-group><article-title>Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells</article-title><source><italic>Anti-Cancer Drugs</italic></source><year>2007</year><volume>18</volume><issue>5</issue><fpage>535</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">17414622</pub-id></citation></ref><ref id="B88"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>W-G</given-names></name><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Adrian</surname><given-names>TE</given-names></name></person-group><article-title>The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2002</year><volume>296</volume><issue>4</issue><fpage>942</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">12200139</pub-id></citation></ref><ref id="B89"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hennig</surname><given-names>R</given-names></name><name><surname>Ding</surname><given-names>X-Z</given-names></name><name><surname>Tong</surname><given-names>W-G</given-names></name><name><surname>Witt</surname><given-names>RC</given-names></name><name><surname>Jovanovic</surname><given-names>BD</given-names></name><name><surname>Adrian</surname><given-names>TE</given-names></name></person-group><article-title>Effect of LY293111 in combination with gemcitabine in colonic cancer</article-title><source><italic>Cancer Letters</italic></source><year>2004</year><volume>210</volume><issue>1</issue><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">15172119</pub-id></citation></ref><ref id="B90"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falcone</surname><given-names>RC</given-names></name><name><surname>Aharony</surname><given-names>D</given-names></name></person-group><article-title>Modulation of ligand binding to leukotriene B4 receptors on guinea pig lung membranes to sulfhydryl modifying reagents</article-title><source><italic>Journal of Pharmacology and Experimental Therapeutics</italic></source><year>1990</year><volume>255</volume><issue>2</issue><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">2173748</pub-id></citation></ref><ref id="B91"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hennig</surname><given-names>R</given-names></name><name><surname>Ventura</surname><given-names>J</given-names></name><name><surname>Segersvard</surname><given-names>R</given-names></name><etal/></person-group><article-title>LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice</article-title><source><italic>Neoplasia</italic></source><year>2005</year><volume>7</volume><issue>4</issue><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">15967119</pub-id></citation></ref><ref id="B92"><label>92</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>MS</given-names></name><name><surname>Diaz</surname><given-names>B</given-names></name><name><surname>Brozinick</surname><given-names>J</given-names></name><etal/></person-group><article-title>LY293111 inhibits tumor cell growth cell growth in vitro through an apparent PPARgamma agonist activity</article-title><conf-name>In: Proceedings 93rd Annual Meeting of American Association for Cancer Research (AACR '02), vol. 43</conf-name><conf-date>April 2002</conf-date><conf-loc>San Francisco, Calif, USA</conf-loc><fpage>957</fpage></citation></ref><ref id="B93"><label>93</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>MS</given-names></name><name><surname>Diaz</surname><given-names>B</given-names></name><name><surname>Copp</surname><given-names>J</given-names></name><etal/></person-group><article-title>The LTB4 receptor antagonist, LY2931111 inhibits tumor cell growth in vitro independent of the LTB4 receptor</article-title><conf-name>In: Proceedings 93rd Annual Meeting of American Association for Cancer Research (AACR '02), vol. 43</conf-name><conf-date>April 2002</conf-date><conf-loc>San Francisco, Calif, USA</conf-loc><fpage>963</fpage></citation></ref><ref id="B94"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Budman</surname><given-names>DR</given-names></name><name><surname>Calabro</surname><given-names>A</given-names></name></person-group><article-title>Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111</article-title><source><italic>Anti-Cancer Drugs</italic></source><year>2004</year><volume>15</volume><issue>9</issue><fpage>877</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">15457128</pub-id></citation></ref><ref id="B95"><label>95</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>GK</given-names></name><name><surname>Budman</surname><given-names>DR</given-names></name><name><surname>Endres</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPAR<italic>&#x003b3;</italic>)</article-title><conf-name>In: Proceedings of the 38th Annual Meeting of the American Society of Clinical             Oncology (ASCO '02), vol. 21</conf-name><conf-date>May 2002</conf-date><conf-loc>Orlando, Fla, USA</conf-loc><comment>abstract 343</comment></citation></ref><ref id="B96"><label>96</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>JP</given-names></name><name><surname>Petrylak</surname><given-names>DP</given-names></name><name><surname>Feit</surname><given-names>K</given-names></name><etal/></person-group><article-title>Phase I and pharmacological trial of LY293111 in combination with gemcitabine</article-title><conf-name>In: Proceedings of the 38th Annual Meeting of the American Society of Clinical             Oncology (ASCO '02), vol. 21</conf-name><conf-date>May 2002</conf-date><conf-loc>Orlando, Fla, USA</conf-loc><comment>abstract 2140</comment></citation></ref><ref id="B97"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baetz</surname><given-names>T</given-names></name><name><surname>Eisenhauer</surname><given-names>E</given-names></name><name><surname>Siu</surname><given-names>L</given-names></name><etal/></person-group><article-title>A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours</article-title><source><italic>Investigational New Drugs</italic></source><year>2007</year><volume>25</volume><issue>3</issue><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">17146732</pub-id></citation></ref><ref id="B98"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>DA</given-names></name><name><surname>Oettle</surname><given-names>H</given-names></name><name><surname>Vervenne</surname><given-names>WL</given-names></name><etal/></person-group><article-title>Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2005</year><volume>23</volume><issue>16s</issue><fpage>p. 4092</fpage></citation></ref><ref id="B99"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Rodriguez</surname><given-names>P-A</given-names></name><name><surname>Gottfried</surname><given-names>M</given-names></name><etal/></person-group><article-title>Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosanoid pathway modulator, in patients with chemotherapy na&#x000ef;ve advanced non-small cell lung carcinoma</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2006</year><volume>24</volume><issue>18s</issue><fpage>p. 7024</fpage></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Immunocytochemistry of PPAR<italic>&#x003b3;</italic> receptor in normal human pancreas and in aPanIN lesion and a pancreatic cancer. The PPAR<italic>&#x003b3;</italic> receptor antibody shows asimilar intensity of nuclear staining in normal ducts and in pancreatic cancercells as well as cells in the PanIN lesion. In contrast, no staining is seen innormal islets, but nuclear staining is seen in islets from tissue adjacent to acancer. These pictures are representative of eight samples of each tissue type. Staining was similar using antibodies from two different commercial sources.</p></caption><graphic xlink:href="PPAR2008-827096.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Comparison of the effects of different concentrations of LY293111 andciglitazone on proliferation of two human pancreatic cancer cell lines (Panc-1and S2-013) after 24 and 96 hours of treatment, measured by thymidineincorporation. LY293111 was approximately 50 times more potent than ciglitazoneat inhibiting proliferation of both cell lines. Data shown is mean&#x000b1;SEM fromfour separate experiments.</p></caption><graphic xlink:href="PPAR2008-827096.002"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Effect of a PPAR<italic>&#x003b3;</italic> receptor antagonist, GW9662 on the inhibition ofproliferation induced by LY293111 in AsPC-1 human pancreatic cancer cells after24 hours of treatment. These cells express both the PPAR<italic>&#x003b3;</italic> receptor and LTB<sub>4</sub> (BLT1 and BLT2) receptors. While GW9662 alone was able to significantlyincrease thymidine incorporation, it was not able to block the inhibitoryeffect of different concentrations of LY293111.</p></caption><graphic xlink:href="PPAR2008-827096.003"/></fig></floats-wrap></article>